News Release

The role of fatty acids in Multiple Myeloma Microenvironments is investigated through the use of Cleanascite™

MONMOUTH JUNCTION, NJ, January 31, 2023 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid binding technology to determine the influence long-chain fatty acids on CD8+ T cell metabolism and function in Multiple Myeloma.

Gudgeon, Bishop, et al. "CD8+ T cell metabolism and function are suppressed by long-chain fatty acid uptake from the bone marrow microenvironment in Multiple Myeloma." (2023).

Multiple Myeloma (MM) is a plasma cell malignancy that develops in the bone marrow. Function of T lymphocytes is impaired in patients with MM and the bone marrow microenvironment is described as hostile for T cell activity. Precise suppressive mechanisms within the bone marrow microenvironment remain poorly defined. In this study T cell phenotype, function and metabolic activity were analysed within paired bone marrow aspirate and peripheral blood samples from 72 patients across the spectrum of MM. The bone marrow microenvironment was also modelled in vitro using autologous plasma co-culture systems.

In vitro modelling confirmed that uptake of bone marrow lipids suppresses CD8 + T function, which was impaired in autologous bone marrow plasma, but rescued by both lipid removal and inhibition of lipid peroxidation. The article states “Removal of BM lipids (using Cleanascite) increased mitochondrial mass in control and MM BM CD8 + T cells (Fig.), accompanied by restoration of IFN-γ and TNF-α expression.”. The article concludes that CD8 + T cells are functionally impaired within the MM bone marrow microenvironment. This is accompanied by decreased mitochondrial mass but elevated uptake of long-chain fatty acids. Blockade of fatty acid transport protein 1 (FATP1) restores CD8 + T cell function in presence of BM lipids and may therefore represent a novel therapeutic target to augment their activity in the bone marrow in MM and improve efficacy of T cell directed therapies. 

“This is now our sixth study whereby Cleanascite™ was used in evaluating the removal of free fatty acids in for in vitro cancer models. These references along with over twenty others, show that Cleanascite™ can help identify a characteristic feature of cell response related to lipid removal. Unlike alternative methods that use solvents, Cleanascite™ is an aqueous suspension product and so post-treatment, it is seamlessly integrates with cellular models of disease. This ultimately helps with investigations such as this, that need to determine whether or not lipids, or factors associated with lipids, impart phenotypic changes to cells.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Link to view our case study, Lipid Removal for Phenotypic Cell Response in Cancer Research (biotechsupportgroup.com)

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords: Multiple Myeloma, CD8+ T cell, long-chain fatty acids, lipid removal, mitochondria, bone marrow microenvironment, Cleanascite™

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development, contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com